Impact assessment of the European Clinical Trials Directive: A longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries

Trials

Volumn 13, Issue , 2012, Pages

  Hartmann, Markus ^a  

^a European Consulting and Contracting in Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SCREENING; EUROPE; EUROPEAN UNION CLINICAL TRIAL DIRECTIVE; FRANCE; FUNDING; GERMANY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; ITALY; LAW; LONGITUDINAL STUDY; NETHERLANDS; OBSERVATIONAL STUDY; ORGANIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY CONTROL; SPAIN; UNITED KINGDOM; DRUG THERAPY; EUROPEAN UNION; LEGAL ASPECT; TIME;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; EUROPE; EUROPEAN UNION; HUMANS; LONGITUDINAL STUDIES; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84860216789     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-53     Document Type: Article

References (37)

1. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009, 360:816-823.
2. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat Rev Drug Discov 2008, 7:13-14.
3. Directive 2001/20/EC of the European Parliament and the Council of 4 Apr 2001 on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Community 2001, L121:34-44.
4. Frewer LJ, Coles D, Champion K, Demotes-Mainard J, Goetbuget N, Ihrig K, Klingmann I, Kubiak C, Lejeune SA, McDonald F, Apperley J. Has the European Clinical Trials Directive been a success?. BMJ 2010, 340:937.
5. European Commission - European Medicines Agency Report on the Conference on the Operation of the Clinical Trials Directive (Directive 2001/20/EC) and Perspectives for the Future. European Commission - European Medicines Agency., http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500011204.pdf
6. Klingmann I. Impact on Clinical Research of European Legislation (ICREL): Project Final Report. , http://www.efgcp.be/downloads/icrel_docs/Final_report_ICREL.pdf
7. European Science Foundation-EMRC - Forward Look Investigator-Driven Clinical Trials. European Science Foundation-EMRC - Forward Look., http://www.esf.org/fileadmin/links/EMRC/FL_IDCT.pdf
8. European Commission Assessment of the functioning of the 'Clinical Trials Directive 2001/20/EC. European Commission., http://ec.europa.eu/health/files/clinicaltrials/docs/2009_10_09_public-consultation-paper.pdf
9. European Commission Assessment of the functioning of the 'Clinical Trials Directive' 2001/20/EC - Summary of responses to the public health consultation paper. European Commission., http://ec.europa.eu/health/files/clinicaltrials/2010_03_30_summary_responses.pdf
10. European Commission Roadmap for a legislative proposal on a Regulation/Directive amending the Clinical Trials Directive 2001/20/EC. European Commission., http://ec.europa.eu/governance/impact/planned_ia/docs/47_sanco_clinical_trials_directive_en.pdf
11. European Commission Revision of the'Clinical Trials Directive' 2001/20/EC. Concept Paper for Public Consultation. European Commission., http://ec.europa.eu/health/files/clinicaltrials/concept_paper_02-2011.pdf
12. European Commission Volume 10 of Eudralex - Clinical Trials. Annex 1: Clinical Trial Application Form. European Commission., http://ec.europa.eu/health/files/eudralex/vol-10/11_an1_14-2005_en.pdf
13. Getz KA. Global Clinical Trial Activity in the Details. Applied Clin Trials 2007, , http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=453243&sk=&date=&pageID=3&searchString=global%20trials
14. Legrand C, Cheix F, Dumais H, Laugel V, De Cremiers F, Dupont C. Clinical trial initiation procedures in Europe: the legal framework and practical aspects. Drug Inf J 1995, 29:201-259.
15. Gluud C, Nikolova D. Likely country of origin in publications on randomised controlled trials and controlled clinical trials during the last 60 years. Trials 2007, 8:7.
16. Murphy SW. Longitudinal studies and determination of risk. Methods Mol Biol 2009, 473:19-37.
17. Hemminki A. Harmful impact of EU clinical trials directive. BMJ 2006, 332:501-502.
18. McMahon AD, Conway DI, MacDonald TM, McInnes GT. The unintended consequences of clinical trials regulations. PLoS Med 2009, 3:e1000131.
19. Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of clinical cancer trials. Eur J Cancer 2006, 42:1322-1330.
20. Hearn J, Sullivan R. The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK. Eur J Cancer 2007, 43:8-13.
21. Filibeck U, Addis A, Tomino C, Martini N. European Clinical Trials Directive: the Italian position. Lancet 2004, 363:1651-1652.
22. Il Ministro della Salute. Decreto Ministeriale 17 dicembre 2004 Prescrizioni e condizioni di carattere generale, relative al l'esecuzione delle sperimentazioni cliniche dei medicinali, con particolare riferimento a quelle ai fini del miglioramento della pratica clinica, quale parte integrante dell'assistenza sanitaria. G.U 2005, 43:26-32. Unofficial English translation: [http://ricerca-clinica.agenziafarmaco.it/sites/default/files/files_wysiwyg/files/Normativa/MD_17_december_2004_noprofit_English.pdf], Il Ministro della Salute. Decreto Ministeriale 17 dicembre 2004.
23. Hartmann M, Hartmann-Vareilles F. The Clinical Trials Directive: how is it affecting Europe's non-commercial research?. PLoS Clinical Trials 2006, 1:e00013.
24. AIFA Research & Development Working Group Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest 2010, 40:69-86. AIFA Research & Development Working Group.
25. Il Ministro della Salute. Decreto Ministeriale 14 Luglio 2009 Requisiti minimi per le polizze assicurative a tutela dei soggetti partecipanti alle sperimentazioni cliniche dei medicinali. (Unofficial English translation: [http://ricerca-clinica.agenziafarmaco.it/sites/default/files/files_wysiwyg/files/Normativa/MD_14_July_2009_English.pdf]), Il Ministro della Salute. Decreto Ministeriale 14 Luglio 2009.
26. UK Department of Health Model clinical trials agreements. UK Department of Health., http://www.dh.gov.uk/en/Aboutus/Researchanddevelopment/AtoZ/DH_4002073
27. Stewart P, Stears A, Tomlinson JW, Brown MB. Regulation - the real threat to clinical research. BMJ 2008, 337:1085-1087.
28. Rawlins M. A new era for UK clinical research?. Lancet 2011, 377:190-192.
29. Gulland A. EU directive threatens UK's "spectacular" record in clinical trials. BMJ 2009, 338:678.
30. Tuffs A. Germany sees rise in post-marketing studies. BMJ 2009, 339:883.
31. Berendt L, Hakansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulson HE. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish medicines agency, 1993-2006. BMJ 2008, 336:33-35.
32. Woods K. Implementing the European clinical trials directive. BMJ 2004, 328:240-241.
33. Karlberg JPE. Globalization of sponsored clinical trials. Nat Rev Drug Discov 2008, 7:458-460.
34. European Medicines Agency Clinical trials submitted in marketing authorisation applications to the EMEA: Overview of patient recruitment and the geographical location of investigator sites. European Medicines Agency., http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500016819.pdf
35. Hartmann M, Hartmann-Vareilles F. How to avoid further legislative fragmentation of clinical research in the European Union. RAJ Pharma 2010, 21:163-168.
36. Kudrin A. Challenges in the clinical development requirements for the marketing authorization of new medicines in Southeast Asia. J Clin Pharmacol 2009, 49:268-280.
37. Hartmann M. Impact of the new legislative framework within the European Union on non-commercial clinical research and investigator-initiated trials: a cross-European analysis with focus on oncology. Master thesis 2005, University of Bonn, Faculty of Mathematics and Science., http://www.dgra.de/studiengang/pdf/master_hartmann_m.pdf